NGS enables broad detection of known and novel viruses in a single assay. Its high sensitivity, specificity, and scalability can meet GMP throughput levels.
- The Promise Of MRD-Guided CAR-T Treatment
- CDMO Quality Oversight: How FDA And Pharma Leaders Are Rethinking Data, AI, And Culture
- Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?
- A QMS That Anticipates Cell And Gene Therapy Quality Challenges
- Using Digital Platforms To Find Your CDMO
- July 2026 — CDMO Opportunities And Threats Report
- ADC CDMO Selection For Small Biotech
- Implementing AI Solutions In GMP While Managing Risk
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Delivering A Registrational GI Trial Through Ongoing Protocol Shifts
A biotech developing bispecific antibodies partnered with a flexible CRO to launch its first U.S. GI oncology trial, requiring strategic insight and full-service clinical support.
-
Simplify Process Scale-Up With An Innovative Single-Use Bioreactor
Consistent cell growth and protein yields from 5 L to 5,000 L show how a unified bioreactor design can simplify scale-up, reduce risk, and accelerate upstream process development in bioproduction.
-
Sterile Filter Membrane Selection For Cell Culture Media Filtration
Membrane design and filtration capacity affect pressure, throughput, and scale-up. See how comparative testing reveals opportunities to reduce required filtration area, capsule use, and changeouts.
-
Manufacturing ADCs: Extractables In Single-Use Systems
Antibody-drug conjugates offer targeted cancer treatment with reduced toxicity. Discover how single-use technologies simplify ADC manufacturing to ensure safety, flexibility, and efficiency.
-
Control pH Adjustment And Reduce Complexity
Learn how automated, banded pH control uses dose-and-wait logic to limit overshoot, account for mixing and buffer effects, and maintain stable setpoints across changing fill volumes.
-
Molecular Approaches To Streamline Cell Therapy Product Analytical Testing
Learn how rapid molecular methods of cell therapy testing like qPCR for mycoplasma, sterility, and lentiviral quantification are key to accelerating product release and timely treatment delivery.
-
Maintain Sterility And Ease In CGT Development, Including Cryopreservation
Sterile connectors streamline cell and gene therapy processes while maintaining sterility. By withstanding extreme temperatures and cryoprotectants, they can ensure product viability during cryopreservation.
-
Overcome Patient-Level Access Barriers For New Medicine
Explore market access from the patient’s perspective and identify five aspects of how people get hold of medicine that should inform commercialization.
-
Accelerating Cell Therapy Discovery With High-Throughput Electroporation
Discover how high-throughput electroporation-based screening can compress your CAR-T optimization timeline while delivering reproducible, scale-ready results across multiple donor samples.
-
Scalability And Reproducibility Of The AAV9 Capture Step
Scaling gene therapies beyond rare diseases demands innovation. Discover a chromatography system that boosts efficiency, protects product integrity, and overcomes viral vector manufacturing challenges.
NEWSLETTER ARCHIVE
- 09.14.26 -- Your Collaborator: mAb Productivity And Robustness
- 09.14.26 -- How To Select The Right Manufacturing Model For Your Pipeline
- 09.12.26 -- Cell & Gene Newsletter - Best Of August
- 09.11.26 -- Why Autoimmune CAR T Needs A New Patient-Centered Playbook — With Dr. Panteli Theocharous
- 09.10.26 -- Is Your Fill/Finish Strategy Ready To Scale?
- Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?
- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- In Vivo CAR T Needs More Than Better Cell Engineering
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections